Open menu Close Previous Next Facebook X LinkedIn YouTube WhatsApp Phone Newsletter Email Location AMSlab AMSvet AMSfood AMSbiopharma CIFGA Nexotech EU

CDTI INNTERCONECTA STEP 2025

Innovación en biotecnología

AMSbiopharma has been awarded funding by the CDTI INNTERCONECTA STEP 2025 programme for the project titled “ADVANCED ANTISENSE OLIGONUCLEOTIDE THERAPIES FOR NEUROMUSCULAR DISEASES”, NEUROAON (ITC-20251291).

The general objective of NEUROAON is to design and develop therapeutic AONs for untreated neuromuscular diseases through rational oligonucleotide design, targeted delivery, and preclinical validation. This project is subsidized by CDTI with FEDER funds 2021–2027.

This collaborative project is led by ARTHEx Biotech, with the participation of AMS Biopharma Laboratory S.L., Polypeptide Therapeutic Solutions S.L., and ProtoQsar 2000 S.L.

Logo_cdti_2024_sin_banderas_soportes_fisicos
Logotipos_rgb_fondoseuropeos_positivo_castellano

Involved companies:

  • AMSbiopharma